指南与共识肝病

AGA临床实践更新:代谢功能障碍与酒精相关肝病的评估和管理专家综述

AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2026-09-22

美国胃肠病学会(AGA)发布专家综述,针对代谢功能障碍与酒精相关肝病(MetALD)提出9条最佳实践建议,涵盖基于每周酒精摄入量(女性约140-350克,男性210-420克)的分类、酒精使用筛查、戒酒建议、无创纤维化评估、影像学检查、营养运动管理、药物治疗及减重手术禁忌等。

要点

  • MetALD分类需结合心脏代谢危险因素和每周酒精摄入量(女性约140-350克,男性210-420克)。
  • 所有脂肪性肝病患者应初始及至少每年评估酒精使用,包括访谈、问卷和生物标志物。
  • 建议所有患者戒酒,采用分层无创策略(如FIB-4)识别低风险并转诊中高风险者。

核心结论

  • MetALD是脂肪性肝病的重要亚类,需基于心脏代谢危险因素和酒精摄入量进行分类。
  • 所有MetALD患者应定期评估酒精使用并建议戒酒,酒精摄入呈剂量依赖性加重肝脂肪变和纤维化进展。
  • 采用分层无创策略评估纤维化,谨慎解读活动性饮酒时的肝脏硬度值。
  • 医疗管理包括饮食咨询、纠正微量营养素缺乏、有氧运动及治疗心脏代谢危险因素。
  • MetALD合并中重度酒精使用障碍应使用药物和行为疗法;减重手术/内镜减重不宜推荐。

研究设计与样本

  • 由AGA临床实践更新委员会委托并批准的专家综述,经内部和外部同行评议。
  • 基于已发表文献回顾和专家意见形成最佳实践建议,未进行系统评价,无正式证据质量分级。

主要发现

  • 酒精消耗在几乎所有慢性肝病(包括MetALD)中以剂量依赖方式增加肝脂肪变积累和纤维化进展。
  • GLP-1和GIP受体激动剂的初步数据提示可能减少酒精渴求和摄入并改善肝脏参数。
  • 美国FDA批准的非肝硬化MASLD治疗(resmetiron和semaglutide)尚未在MetALD中正式研究。

关键数值与推荐

  • MetALD的酒精摄入阈值:女性约140-350克/周,男性210-420克/周(理想情况下基于≥3个月)。
  • 所有脂肪性肝病患者应初始及至少每年通过访谈、经验证的酒精使用问卷和/或血清/尿液酒精生物标志物评估酒精使用。
  • 采用分层无创策略,结合基于血液的生物标志物和简单纤维化评分(如Fibrosis-4指数),将中危或高危患者转诊至二线检查(如弹性成像或血清ELF测试)。
  • 振动控制瞬时弹性成像和磁共振技术可客观评估纤维化分期和脂肪变负担,但活动性饮酒时肝脏硬度值应谨慎解读。
  • MetALD医疗管理应包括饮食咨询、补充微量营养素(叶酸、硫胺素、维生素D)、有氧运动及治疗心脏代谢危险因素。

临床怎么用

  • 临床中应使用每周酒精摄入量阈值(女性140-350克,男性210-420克)区分MetALD。
  • 对所有脂肪性肝病患者定期(至少每年)通过访谈、问卷和生物标志物评估酒精使用。
  • 采用FIB-4等简单纤维化评分进行初始风险分层,中高危患者转诊弹性成像或ELF检测。
  • 为MetALD患者提供戒酒建议、饮食咨询、微量营养素补充和有氧运动指导。
  • MetALD合并中重度酒精使用障碍应使用药物治疗和行为疗法;避免推荐减重手术。

局限性

  • 未进行系统评价,最佳实践建议无正式证据质量或推荐强度分级。
  • 美国FDA批准的非肝硬化MASLD治疗在MetALD中尚未正式研究,仅有初步数据。
  • 活动性饮酒可能暂时增加肝脏硬度值,影响弹性成像解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: Steatotic liver disease (SLD) is the leading cause of chronic liver disease and liver-related mortality in the United States. The 2023 multisociety consensus nomenclature was intended to develop a more evidence-based framework regarding the differing forms of SLD, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction- and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease. The purpose of this American Gastroenterological Association (AGA) Clinical Practice Update expert review is to provide Best Practice Advice regarding the diagnosis, staging, and treatment of MetALD. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership. The document underwent internal peer review by the Clinical Practice Updates Committee and external peer review through the standard procedures of Clinical Gastroenterology and Hepatology. These BPA statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these BPA statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE STATEMENTS BEST PRACTICE ADVICE 1: Patients with SLD can be classified into MASLD, MetALD, and alcohol-associated liver disease categories by the presence of cardiometabolic risk factors and the quantity of alcohol consumed in grams per week (ideally over ≥3 months), using the thresholds of ≈140 to 350 g/wk in women and 210 to 420 g/wk in men for MetALD. BEST PRACTICE ADVICE 2: All patients with steatotic liver disease, including MetALD, should be assessed initially and at least annually thereafter for alcohol use via patient interview, completion of validated alcohol use questionnaires, and/or measurement of serum and/or urine alcohol biomarkers. BEST PRACTICE ADVICE 3: Alcohol consumption increases the extent of hepatic steatosis accumulation and fibrosis progression in a dose-dependent manner in nearly all forms of chronic liver disease, including those with MetALD. Therefore, all patients should be advised to discontinue alcohol use, recognizing that abstinence may be preceded by periods of use reduction and intermittent use. BEST PRACTICE ADVICE 4: A tiered, noninvasive strategy that combines routine blood-based biomarkers with simple fibrosis scores, such as the Fibrosis-4 Index, should be used to identify low-risk patients with MetALD and to triage those at indeterminate or high risk to second-line tests (eg, elastography or serum Enhanced Liver Fibrosis test) for detection of advanced fibrosis and cirrhosis. BEST PRACTICE ADVICE 5: Vibration-controlled transient elastography and magnetic resonance-based techniques are noninvasive tools that objectively assess the fibrosis stage and steatosis burden in patients with MetALD; however, liver stiffness values should be interpreted cautiously in the presence of active alcohol use, which can transiently increase stiffness. BEST PRACTICE ADVICE 6: Medical management of MetALD should include dietary counseling and replenishment of micronutrient deficiencies (folate, thiamine, vitamin D) as well as aerobic exercise to improve body weight and muscle mass, along with treatment of concomitant cardiometabolic risk factors. BEST PRACTICE ADVICE 7: The safety and efficacy of United States Food and Drug Administration-approved treatments for noncirrhotic MASLD (ie, resmetiron and semaglutide) has not been formally studied in MetALD. However, preliminary data suggests that glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists may reduce alcohol cravings and consumption and improve hepatic parameters. BEST PRACTICE ADVICE 8: Medical management of patients with MetALD and moderate or severe alcohol use disorder should include use of alcohol use disorder pharmacotherapy and behavioral approaches to reduce alcohol consumption. BEST PRACTICE ADVICE 9: Endobariatric and bariatric surgery are not advisable for patients with MetALD due to the lack of safety and efficacy data as well as concerns regarding accelerated liver disease progression with continued alcohol use after surgery.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Arab JP, Malhi H, Winder GS, et al. AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review. Clin Gastroenterol Hepatol. 2026. PMID: 42776095. doi:10.1016/j.cgh.2026.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。